Get the Stockscreener App
6.69
7.99%
-0.57
Cybin Inc stock is traded at $6.69, with a volume of 1.31M.
It is down -7.99% in the last 24 hours and up +9.87% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$7.26
Open:
$7.4
24h Volume:
1.31M
Relative Volume:
1.83
Market Cap:
$157.70M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-32.21
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
+2.61%
1M Performance:
+9.87%
6M Performance:
+2.77%
1Y Performance:
-33.13%
1-Day Range:
$6.48
$7.4375
1-Week Range:
$6.48
$8.00
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.685 | 200.49M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Live market analysis of Cybin Inc.Earnings Beat & Accurate Entry and Exit Point Alerts - newser.com
Can technical indicators confirm Cybin Inc.’s reversalQuarterly Earnings Report & Consistent Profit Focused Trading Strategies - newser.com
Long term hold vs stop loss in Cybin Inc.Portfolio Return Summary & Safe Entry Zone Identification - newser.com
Custom strategy builders for tracking Cybin Inc.July 2025 Spike Watch & Long-Term Investment Growth Plans - newser.com
Cybin to Participate at the 2025 Milken Institute Future of Health Summit - The Joplin Globe
Is Cybin Inc. stock ready for a breakoutRisk Management & Consistent Profit Alerts - newser.com
What market sentiment indicators show for Cybin Inc. Common Shares stock2025 Macro Impact & Real-Time Volume Analysis - newser.com
Can Cybin Inc. Common Shares stock surprise markets with earningsQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
Price momentum metrics for Cybin Inc. explained2025 Key Lessons & Safe Investment Capital Preservation Plans - newser.com
Is Cybin Inc. stock cheap at current valuationJuly 2025 Summary & Low Drawdown Trading Strategies - newser.com
Will Cybin Inc. stock benefit from sector rotationQuarterly Portfolio Review & Reliable Intraday Trade Plans - newser.com
Can Cybin Inc. stock deliver surprise earnings beatJuly 2025 Setups & Weekly Watchlist for Hot Stocks - newser.com
How Cybin Inc. stock compares to growth peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - newser.com
Using Python tools to backtest Cybin Inc. strategiesSwing Trade & Real-Time Volume Trigger Notifications - newser.com
Will Cybin Inc. (R7E) stock profit from automation waveWeekly Investment Report & Community Verified Swing Trade Signals - newser.com
Is Cybin Inc. stock oversold or undervaluedQuarterly Profit Summary & Weekly Watchlist of Top Performers - newser.com
What hedge fund activity signals for Cybin Inc. stockGap Down & Daily Risk Controlled Trade Plans - newser.com
Cybin Inc. (NYSEAMERICAN:CYBN) Short Interest Update - MarketBeat
Will Cybin Inc. stock gain from strong economyDip Buying & Free Fast Entry Momentum Trade Alerts - newser.com
Why Cybin Inc. Common Shares stock is a strong analyst pickJuly 2025 Update & Fast Gain Stock Trading Tips - newser.com
Is Cybin Inc. (R7E) stock a fit for income portfoliosRate Cut & AI Optimized Trading Strategy Guides - newser.com
Cybin raises $175 million in direct offering to fund clinical programs - Investing.com Australia
Cybin raises $175 million in direct offering to fund clinical programs By Investing.com - Investing.com South Africa
[6-K] CYBIN INC. Current Report (Foreign Issuer) | CYBN SEC FilingForm 6-K - Stock Titan
Cybin Closes $175 Million Direct Offering - MarketScreener
Cybin Announces Closing of $175 Million Registered Direct Offering - The Joplin Globe
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Cap:
|
Volume (24h):